|
|
|
|
|
| First Name: | Seong | | Last Name: | An | | Title: | Professor | | Advanced Degrees: | Ph. D. | | Affiliation: | Kyungwon University | | Department: | Bionano Technology | | Street Address 1: | Mirae Hall Rm 108, Kyungwon University | | Street Address 2: | San 65, Bokjung-dong, Sujung-gu | | City: | Sungnam-si | | State/Province: | Geonggi-do | | Zip/Postal Code: | 461-701 | Country/Territory: | Korea, South | | Phone: | +82183449633 | | Fax: | +82317508755 | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports no financial or other potential conflicts of interest. [Last Modified: 21 March 2009]
|
Prion Diseases, Stroke and Trauma, Neuromuscular Disorders (ALS, etc.), Aging Process, Alzheimer Disease, Tauopathies, Parkinson Disease, Polyglutamine Disorders (Huntington's, etc.), Neurodevelopmental Disorders (Down syndrome, etc.)
|
Neurotransmission, Diagnosis, Proteomics, Tau/Cytoskeleton, Oxidative Stress, A-beta PP/A-beta, Neuroimmunology, Protein structure/chemistry, Drug screening, Neurobiology, Neuropathology
|
University, Research institute
|
Kyungwon University (2007-present) Assistant Professor
Development of the early neurodegenerative disease detection systems
Understanding the protein folding/misfolding in diseases.
Development of the pathogen detections using POCT assays and devices.
PeopleBio Inc. (2003-2007) Research Fellow
Development of the TSE blood detection system
Understanding the protein folding/misfolding in diseases, prion.
Conformational antibody designing, especially in prion diseases.
Strong understanding of designing novel substrates and inhibitors, and detection systems for any proteases or proteins.
Cornell University (2002-2005) Visiting Scientist
Understanding the protein folding/misfolding in diseases, prion.
American Diagnostica, Inc. (1999-2002) Senior Research Scientist
Development of new assays for proteins in blood coagulation, fibrinolysis and anti-angiogenesis.
Invented the chromogenic methods of assaying active and total TAFI in the purified system and in plasma.
Development of anti-cancer drugs.
Synthesis of anti-cancer drugs for in vitro and in vivo studies.
Development of the novel HTS assay system for screening the leading inhibitors in uPA/uPAR system.
Development of the novel HTS assay system for screening the leading inhibitors in Plasminogen Activator inhibitor (PAI) system.
Development, and optimization of the PAI inhibitors in conjunction with PAI’s multi-interactions with vitronectin, uPAR, integrins, and cancer cells.
Development of the in-house chemical libraries and their combinatorial synthesis.
Cornell University (1997-1999) Post-Doctoral Fellow
Structural Biology and Protein Biochemistry of thrombin interactions in Thrombosis.
Protein Folding: Pro cis-trans isomerization in peptides from ribonuclease A.
Locked a proline analog, dimethylproline in to 100 % cis conformation confirmed using NMR spectroscopy.
Carnegie Mellon University Protein Biochemistry and NMR Spectroscopy of peptides/proteins in Fibrinolysis.
Graduate Research Assistant. (1990-1997)
Investigated the structural and functional properties of the modules in plasminogen/angiostatin, especially protein-protein/ligand binding interactions of kringle domains.
Screening possible ligands for the binding interactions, small ligands, peptides, and proteins, against single or multi kringle domains.
Collaborated in finding K5 as a novel angiogenesis inhibitor with Dr. Cao from Dr. Folkman’s group and Dr. Davidson from Abbott Research Labs.
Determined two chains of fibronectin are connected in anti-parallel fashion.
National Institute. of Environmental Health & Science (NIH) (1987-1989)
Research Assistant at L. of Molecular & Integrative Neuroscience
Study on the role of cellular proto-oncogenes as a possible mediator of changes in gene expression.
LG Central Research Institute Dae Duk Science Town, Korea (1989)
NSF/KSEA Summer Scholar at Dept. of Fine Chemicals
Synthesis of cardiovascular and anti-angiogenesis drug, captopril.
University of North Carolina at Chapel Hill
Undergraduate Research (1989):
Cytochrome C: Expression and Purification of Cytochrome C. Replacement of histidine with arginine in the Heme active site. Study on the spectra of the cytochrome-C.
Research Assistant (1985-1987) UNC Medical School, Dept. of Biochemistry |
1. A Novel Fibrinogen Variant (Fibrinogen Seoul II; AGln328Pro) Characterized by Impaired Fibrin -chain Cross-linking. Rojin Park, Hyun-Ju Doh, Seong-Soo A An, Jong-Rak Choi, Kwang-Hoe Chung, and Kyung-Soon Song, Blood (2006), 108: 1919-1924
2. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? Antovic JP, Schulman S, An SS, Greenfield RS, Blomback M. Scand J Clin Lab Invest. (2004);64(8):745-51.
3. Differential Epitope-Mapping of the Two Forms of the Prion Protein: Alterations at the C-terminus, Bulletin of the Korean Chemical Society, Korean Chemical Society, 2008, 2403, Seong Soo A. An
4. Structural Examination of the Influence of Phosphorylation on the Binding of Fibrinopeptide A to Bovine Thrombin. M. C. Maurer, J.-L. Peng, S. S. An, J.-Y. Trosset, A. Henschen-Edman, Harold A. Scheraga, (1998) Biochemistry, 37, 5888.
5. Binding of thrombin activable fibrinolysis inhibitor (TAFI) to plasminogen may play a role in the fibrinolytic pathway., Bulletin of the Korean Chemical Society, Korean Chemical Society, 2008, 2209, Seong Soo A. An
6. Detecting Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) and Inactivated TAFIa (TAFIai) in Normal and Hemophilia A Plasmas, Bulletin of the Korean Chemical Society, Korean Chemical Society, 2008, 77, Seong Soo A. An
7. MWCNT/fibrin Bionanocomposites by in situ Enzymatic Polymerization, Bulletin of the Korean Chemical Society, Korean Chemical Society, 2008, 150, Seong Soo A. An
8. Kringle 5 of plasminogen: a novel inhibitor for endothelial cell growth. Yihai Cao, A. Chen, Seong Soo A. An, Richard-Weidong Ji, Yumei Cao, Don Davidson, Miguel Llinas, & Andrew Chen, (1997) J Biol Chem, 272: 22924.
9. Structural/functional properties of the Glu1 HSer57 N terminal fragment of human plasminogen: conformational characterization and interaction with kringle domains. Seong Soo A. An, Daniel Marti, Cristina Carreño, Fernando Albericio, Johann Schaller, and Miguel Llinas, (1998) Protein Science, 7: 1947.
10. Lysine 50 is a most likely site for anchoring the plasminogen N terminal domain to lysine binding kringles. Seong Soo A. An, Cristina Carreno, Daniel Marti, Johann Schaller, Fernando Albericio, and Miguel Llinas, (1998) Protein Science, 7:1960.
|
Blood diagnostic methods for Early AD and drug screen |
1. Pathology of cerebrospinal fluid and interstitial fluid of the CNS : Significance for Alzheimer disease, prion disorders and Multiple sclerosis, WELLER R. O. Journal of neuropathology and experimental neurology 1998, vol. 57, no10, pp. 885-894
2. Delineating common molecular mechanisms in Alzheimer's and prion diseases. Kevin J. Barnham, Roberto Cappai, Konrad Beyreuther, Colin L. Masters1, and Andrew F. Hill. Trends in Biochemical Sciences Volume 31, Issue 8, August 2006, Pages 465-472
3.Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators. Frédéric Checler and Bruno Vincent Trends in Neurosciences Volume 25, Issue 12, 1 December 2002, Pages 616-620 |
Blood diagnostic methods for Early AD and drug screen |
Oligomers exist in blood and can be detected through oligomer specific assay. |
Need to test various AD patient blood from various MCI and AD preclinical stages. |
|
|
|
|
|
|
Home
